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It is now generally recognised that health systems
internationally have resource constraints and need to
set priorities in selecting the interventions they fund.
Hence considerations of value for money are central in
health policy worldwide. Cost-effectiveness analysis is a
formal assessment of value, and is central to how
many health care systems make resource allocation
decisions. The purpose of clinical trials is to generate
evidence to support various types of decision making,
and an increasing number of trials are designed pri-
marily to inform health system decisions (e.g. the
NIHR Health Technology Assessment Programme in
the UK).
Consequently, the process of designing a clinical trial
and determining whether it is a priority for research
funding needs an explicit consideration of whether it
can contribute to better decisions in the future. This
need to tie trials to ultimate decisions about cost effec-
tiveness is at odds with the role that economic analysis
has generally assumed in clinical trials over the last 20
years - i.e. trials being designed largely to address clini-
cal questions but offering some add-on economic data
to facilitate some form of cost effectiveness analysis
when the trial reports.
Analytical methods exist which assess the value of
trials in terms of the likelihood of their improving
resource allocation decisions. Based on Bayesian deci-
sion theory, these methods quantify the uncertainty
relating to the most cost effective approach to managing
a specific patient group based on existing evidence, cou-
ple this with factors such as the size of the patient
population to estimate the expected value of perfect
information which can be used to begin prioritising
trials. Extensions to these methods consider the appro-
priateness of specific trial designs by assessing their
marginal costs and benefits in terms of reduction in the
cost of decision uncertainly. These methods have been
used within the HTA Programme and there are exam-
ples of impact in trial funding decisions. They are, how-
ever, perceived as being complex and requiring
significant analysis. Although this perception can be
challenged, there is undoubtedly a need for methods
that can be applied routinely to assess the potential trial
value. These might include the need for all trial propo-
sals to include modelling to establish a plausible effect
size which is sufficient to demonstrate an intervention’s
cost-effectiveness in the context of all existing evidence.
This modelling would also be used to justify design fea-
tures such as the choice of comparators, endpoints and
follow-up periods.
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